Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 5/2007

Content (15 Articles)

Original Article

WP760, a melanoma selective drug

Mingzhong Zheng, Waldemar Priebe, Eugene T. Walch, Katherine G. Roth, Mikyung Han, Chi-Hui Tang, Sangkyou Lee, Nancy J. Poindexter, Izabela Fokt, Elizabeth A. Grimm

Original Article

Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours

S. A. Veltkamp, H. Rosing, A. D. R. Huitema, M. R. Fetell, A. Nol, J. H. Beijnen, J. H. M. Schellens

Original Article

Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model

Sarah Brem, Betty Tyler, Khan Li, Gustavo Pradilla, Federico Legnani, Justin Caplan, Henry Brem

Original Article

Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer

Jeffrey A. Meyerhardt, Jeffrey W. Clark, Jeffrey G. Supko, Joseph P. Eder, Shuji Ogino, Clinton F. Stewart, Ferdinando D’Amato, Janet Dancey, Peter C. Enzinger, Andrew X. Zhu, David P. Ryan, Craig C. Earle, Robert J. Mayer, Ann Michelini, Kate Kinsella, Charles S. Fuchs

Original Article

Comparison between sonodynamic effect with protoporphyrin IX and hematoporphyrin on sarcoma 180

QuanHong Liu, XiaoBing Wang, Pan Wang, LiNa Xiao, Qiao Hao

Original Article

Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation

Masa-Aki Shibata, Yukihiro Akao, Eiko Shibata, Yoshinori Nozawa, Tetsuro Ito, Satoshi Mishima, Junji Morimoto, Yoshinori Otsuki

Open Access Original Article

Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients

Mitsugu Kochi, Masashi Fujii, Noriaki Kanamori, Teruo Kaiga, Kazuo Aizaki, Toru Takahashi, Tadatoshi Takayama

Original Article

Role of NADPH cytochrome P450 reductase in activation of RH1

Asher Begleiter, Marsha K. Leith, Daywin Patel, Brian B. Hasinoff

Original Article

Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study

Joaquín Casal, Margarita Amenedo, José Ramón Mel, Luis Miguel Antón, Rubén Rodríguez-López, Rafael López-López, Ana González-Ageitos, Javier Castellanos, Manuel Constenla, José L. Tisaire

Original Article

Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy

G. Pentheroudakis, P. Pappas, V. Golfinopoulos, G. Fountzilas, M. Nikolaidou, V. A. Boumba, T. Vougiouklakis, L. Nikiforidis, E. Tzamakou, O. Siarabi, M. Marselos, N. Pavlidis

Original Article

Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice

Chun-Ling Dai, Hui-Yu Xiong, Li-Fen Tang, Xu Zhang, Yong-Ju Liang, Mu-Sheng Zeng, Li-Ming Chen, Xiao-Hong Wang, Li-Wu Fu

Original Article

The inhibition of glutamine synthetase sensitizes human sarcoma cells to l-asparaginase

S. Tardito, J. Uggeri, C. Bozzetti, M. G. Bianchi, B. M. Rotoli, R. Franchi-Gazzola, G. C. Gazzola, R. Gatti, O. Bussolati

Original Article

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

Thomas E. Stinchcombe, Mark A. Socinski, Christine M. Walko, Bert H. O’Neil, Frances A. Collichio, Anastasia Ivanova, Hua Mu, Michael J. Hawkins, Richard M. Goldberg, Celeste Lindley, E. Claire Dees

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine